{"filings":[{"id":1278477,"accession_number":"0001493152-26-030147","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-06-25T20:52:22+00:00","items":["1.01","8.01"],"status":"ready","headline":"INVO Fertility acquires 100% of HRCFG for $175K; regains Nasdaq compliance on timely filings","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of HRCFG membership interests for total consideration of $175,001; $1 paid at close, $175K deferred.","Deferred consideration: $48K paid in equal monthly installments over 9 months starting Oct 2026; $127K from HRCFG free cash flow.","Alabama JV (Innovative Fertility Specialists) now fully consolidated into INVO's financials prospectively.","Nasdaq Staff notified company on June 23, 2026 that it is compliant with Timely Filing Rule after filing 10-Q on June 22; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1177956,"accession_number":"0001493152-26-029517","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-06-22T13:05:10+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility Q1 revenue up 23% to $2.0M; net loss widens on warrant charge, balance sheet strengthened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.02M (+23% YoY); clinic revenue $1.98M (+22%) driven by organic growth and Family Beginnings acquisition.","Net loss from continuing ops $5.5M (incl. $3.8M non-cash warrant remeasurement) vs $1.5M prior year.","Adjusted EBITDA -$1.26M vs -$0.6M; investments in personnel and infrastructure for future clinic expansion.","Eliminated all Series C-2 Preferred ($2.4M) and warrant liabilities ($1.9M); cash rose to $4.9M from $2.1M at Dec 2025.","Stockholders' equity more than doubled to $15.0M (108% increase); total liabilities down 26% to $9.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1085916,"accession_number":"0001493152-26-028910","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-06-16T21:00:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"INVO Fertility files investor presentation for Planet MicroCap Conference; exhibit text not provided in snippet","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation (Exhibit 99.1) for use at the Planet MicroCap Conference on June 17, 2026.","Presentation posted to the 'Investors' section of the company website on June 16, 2026.","The filing states the presentation addresses current and long-term operations, performance, and industry conditions, but specific figures are not available from the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788237,"accession_number":"0001493152-26-026777","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-06-02T12:40:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6,841,250, up 5% from $6,532,000; consolidated clinic revenue up 4% to $6.72M.","Net loss from continuing operations improved to $(5.3)M from $(7.7)M; adjusted EBITDA $(3.2)M vs $(2.2)M.","Raised $11.5M in gross proceeds from Dec 2025 and Jan 2026 financings; Series C-2 Preferred converted/retired.","Acquired Indiana-based Family Beginnings in Feb 2026; it had $1.2M revenue and $0.2M net income TTM Sep 2025.","Patent issued for modified INVOcell device extending protection through 2040; total common shares ~1.8M as of June 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788161,"accession_number":"0001493152-26-026772","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-06-02T12:30:27+00:00","items":["4.02","9.01"],"status":"ready","headline":"INVO Fertility restates 2025 Q1-Q3 financials; non-reliance due to accounting errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on unaudited 10-Qs for Q1-Q3 2025 due to errors in derivative, debt extinguishment, and preferred stock classification.","Errors do not impact revenue or operations; limited to asset, liability, equity, and net income line items.","Restatement to be included in the 2025 Form 10-K; historical amounts will be recast in future filings.","Audit committee and management discussed the issues with independent auditor WithumSmith+Brown, PC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92733,"accession_number":"0001493152-26-019593","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"INVO Fertility receives Nasdaq deficiency notice for late 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 23, 2026, for failing to file 2025 Form 10-K by April 15, 2026.","Delay is due to complex accounting matters: tax provision, warrant accounting, and variable interest entity.","Company has 60 days to submit a compliance plan; Nasdaq may grant up to 180-day extension to October 13, 2026.","Stock continues trading on Nasdaq under symbol IVF; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103817,"accession_number":"0001493152-26-014227","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"INVO Fertility to effect 1-for-5 reverse stock split effective March 27, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio: 1-for-5; effective 12:01 a.m. ET on March 27, 2026.","Post-split shares outstanding approx. 1,615,419; authorized shares reduced to 50,000,000.","No fractional shares; registered holders rounded up; beneficial holders receive cash.","CUSIP changes to 44984F880; trading symbol 'IVF' and Nasdaq listing unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103816,"accession_number":"0001493152-26-007830","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","2.01","5.03","3.02","8.01","9.01"],"status":"ready","headline":"INVO Fertility closes acquisition of Family Beginnings clinic for $760K (cash + preferred stock)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $760K: $360K cash (net $210K after $150K holdback) plus 400 shares of Series D Preferred ($400K).","Clinic generated ~$1M revenue and ~$0.2M net income for 9 months ended Sep 30, 2025 (18% of INVO's clinic revenue).","Dr. James Donahue to continue leading clinic under multi-year agreement; existing care team remains in place.","Series D Preferred convertible at $1.20/share, subject to anti-dilution adjustments, with 4.99% beneficial ownership cap.","Lease for 4,387 sq ft at 8435 Clearvista Plaza, Indianapolis; $132,398.61 annual rent with 2% annual escalator."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103815,"accession_number":"0001493152-26-004484","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"INVO Fertility raises $7.5M via warrant exercise; issues new warrants for 9.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises 4,733,728 existing warrants at reduced $1.59 price, gross proceeds ~$7.5M.","Company issues new unregistered warrants to purchase up to 9,467,456 shares at $1.59.","New warrants exercisable only after shareholder approval, expire 5.5 years later.","Company agrees to file resale registration statement and avoid variable rate transactions for a period.","Maxim Group acts as exclusive financial advisor, receiving 6.5% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103814,"accession_number":"0001493152-26-003628","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"INVO Fertility shareholders approve increase in authorized shares from 6.25M to 250M and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 6,250,000 to 250,000,000 via Certificate of Amendment filed Jan 22.","Shareholders approved issuance of up to 4,733,728 shares upon exercise of warrant from Dec 2025 private placement.","Stock incentive plan amended to increase available shares to 1,000,000 (approx. 10% of fully-diluted shares).","Ratification of WithumSmithBrown, PC as independent auditor for fiscal 2025 approved with 865,418 for, 39,637 against.","All proposals passed; quorum of 944,054 shares represented at special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103813,"accession_number":"0001493152-26-000592","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"INVO Fertility appoints Terah Krigsvold as CFO, Andrea Goren moves to Chief Business Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terah Krigsvold promoted from controller to CFO effective Dec 30, 2025; base salary $250k, bonus up to 50%.","Andrea Goren resigns as CFO, becomes Chief Business Officer and CEO of INVO Centers LLC; same $250k salary.","Goren to focus on fertility clinic acquisitions and new clinic launches, leveraging $1B transaction experience.","Both executives eligible for grants under 2019 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120080,"accession_number":"0001493152-25-028070","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"INVO Fertility signs definitive agreement to acquire Indiana fertility clinic Family Beginnings for $750K","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $750K: $350K cash (less $150K holdback) plus $400K in Series D convertible preferred stock.","Family Beginnings generated $1.2M revenue and $0.2M net income in trailing 12 months ended Sep 30, 2025.","Closing expected by Feb 27, 2026; Dr. James Donahue to continue leading clinic under three-year employment.","Acquisition of non-clinical assets; clinical assets held by new PC under management services agreement.","Expands INVO's fertility clinic footprint in Midwest; aligns with strategy to acquire and operate clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120079,"accession_number":"0001493152-25-026427","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"INVO Fertility raises $4.0M in private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from 2,366,864 shares/pre-funded warrants plus 4,733,728 common warrants at $1.69 combined.","Warrants exercisable at $1.69 per share, subject to shareholder approval, expiring five years from approval.","Net proceeds: up to $300k for Family Beginnings acquisition, up to $938k for debt, balance for working capital.","Maxim Group receives 8% placement fee and warrants for 118,343 shares at $2.1125 per share.","Company agrees to 60-day lockup on equity issuance; will file resale registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120078,"accession_number":"0001493152-25-025977","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"INVO Fertility announces 1-for-8 reverse stock split effective Nov 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Every 8 pre-split shares converted into 1 share; fractional shares rounded up.","Post-split shares outstanding approximately 1,891,151; authorized shares reduced to 6,250,000.","CUSIP changed to 44984F807; trading symbol remains IVF on Nasdaq.","Reverse split became effective pre-market on November 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120077,"accession_number":"0001493152-25-023779","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility Q3 revenue up 23% to $1.76M; net loss widens to $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,757,094 (+23% YoY); clinic revenue $1,722,223 (+21% YoY).","Net loss $(2.6)M vs $(1.6)M; Adjusted EBITDA $(947,568) vs $(945,949).","INVOcell device revenue grew 130% YoY on training support and pricing.","Company expects to complete at least one acquisition in coming months.","Federal policy change in Oct 2025 allows standalone infertility benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":-17.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":5257933.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120076,"accession_number":"0001493152-25-018911","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["3.02","1.01"],"status":"ready","headline":"INVO Fertility sells $500k of Series C-2 Preferred to existing holder; conversion price set at $0.6285","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Institutional investor exercised Additional Investment Right to buy 500 shares of Series C-2 Preferred for $500,000 cash.","Conversion price on C-2 Preferred adjusted to $0.6285 per share following the exercise.","Securities issued without registration under Section 4(a)(2) and Rule 506 of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120075,"accession_number":"0001493152-25-017752","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["3.02","1.01"],"status":"ready","headline":"INVO Fertility issues $200k Series C-2 Preferred to existing holder at $0.6643 conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Institutional investor exercised Additional Investment Right to acquire 200 shares of C-2 Preferred for $200,000 cash.","Conversion price of C-2 Preferred adjusted to $0.6643 per share as a result of the exercise.","Securities issued without registration under Section 4(a)(2) and Rule 506 of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120074,"accession_number":"0001493152-25-016850","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"INVO Fertility settles litigation with Dr. Pritts for $6.01M; issues preferred shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement requires Wood Violet to pay Dr. Pritts $6,010,000 in installments through Dec 2026, with $1M already paid.","Remaining payments: $755k due Sep 30, 2025; $755k Dec 31, 2025; $1M Mar 31, 2026; $2M Jun 30, 2026; $500k Dec 31, 2026.","If INVO raises >$2M in any 6-month period, 25% of excess funding accelerates settlement payments.","Institutional investor exercises Additional Investment Right, acquires 400 shares of Series C-2 Preferred for $400k cash, conversion price adjusted to $0.7141.","Settlement terminates all transaction documents, purchase price adjustments, and restrictive covenants; Dr. Pritts released from non-compete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136664,"accession_number":"0001493152-25-016076","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"INVO Fertility exchanges $1.34M convertible debenture for Series C-2 convertible preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five Narrow Lane LP exchanged its 7% convertible debenture due Feb 2026 for Series C-2 Preferred stock with $1,334,000 stated value.","Company issued 467 additional Series C-2 Preferred shares as part of the exchange consideration.","Debenture fully extinguished; total outstanding reduced by the exchanged amount.","Exchange executed under registration exemptions; no new cash proceeds raised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136663,"accession_number":"0001493152-25-015821","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"INVO Fertility restructures Decathlon loan; payment up $20k/mo, interest multiples raised","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Monthly loan payment increased by $20,000 beginning August 2025.","Minimum Interest multiples rose 0.15 effective Dec 1, 2024 due to failure to raise $1M equity by Nov 30, 2024.","Lender waived default arising from Pritts Settlement consent judgment over $50,000.","Company to reimburse lender $17,488 for fees and expenses related to amendments and settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136662,"accession_number":"0001641172-25-027201","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["3.02","1.01"],"status":"ready","headline":"INVO Fertility issues $200k Series C-2 Preferred to existing holder, conversion price $0.7362","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Institutional investor exercises Additional Investment Right, buys 200 shares of C-2 Preferred for $200,000 cash.","Conversion price on existing C-2 Preferred adjusts to $0.7362 per share as a result of the exercise.","Shares sold and issuable common stock are exempt under Section 4(a)(2) and Rule 506; no SEC registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136661,"accession_number":"0001641172-25-026757","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"INVO Fertility dismisses M&K, appoints Withum as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["M&K dismissed effective Sept 5, 2025; audit committee approved change.","Withum appointed as independent auditor effective same date.","M&K's 2023 and 2024 audit reports expressed substantial doubt about going concern.","No disagreements or reportable events occurred during the past two fiscal years.","M&K furnished a letter to the SEC, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136660,"accession_number":"0001641172-25-025270","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"INVO Fertility exchanges debenture with Five Narrow Lane, reduces principal to $1.75M and issues preferred stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal reduced to $1,751,343.75 via $1,300,000 exchange for 325 Series C-2 Preferred shares with $1.3M stated value.","Interest rate remains 7% per annum; maturity February 11, 2026; conversion price $1.4765 per share.","Monthly redemption provisions removed; no prepayment without holder consent.","Registration deadline for resale of shares extended to August 29, 2025; effectiveness deadline to Sept 30, 2025 (or Oct 31 if full review).","Side letter also extends filing deadline for new warrants registration to August 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136659,"accession_number":"0001641172-25-024338","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.","Net loss from continuing operations $(3.2)M vs $(2.2)M in Q2 2024.","Adjusted EBITDA $(587,230) vs $(509,623) in prior year period.","Completed divestiture of majority stake in NAYA Therapeutics; retains minority position.","Launched telehealth and PRP therapy at Wisconsin clinic; received patent allowance for INVOcell device through 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":-75.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3500839.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136658,"accession_number":"0001641172-25-021900","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["3.02","1.01"],"status":"ready","headline":"INVO Fertility issues $200K Series C-2 Preferred shares, conversion price at $1.8909","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Institutional investor exercises Additional Investment Right to purchase 200 Series C-2 Preferred shares for $200,000 cash.","Conversion price on C-2 Preferred adjusts to $1.8909 per share.","Securities issued under Section 4(a)(2) and Rule 506 exemption; shares issuable upon conversion unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136657,"accession_number":"0001641172-25-020699","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.02","1.01","5.07"],"status":"ready","headline":"INVO Fertility authorized shares increased to 50M from 1.39M; issues $200k preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing authorized common shares from 1,388,888 to 50,000,000; vote: 643,612 for, 219,764 against, 5,008 abstain.","Issued 200 shares of Series C-2 Convertible Preferred Stock for $200,000 cash to an institutional investor/existing holder.","Conversion price on C-2 Preferred adjusted to $0.6651 pre-split; post 1-for-3 reverse split effective July 21, 2025, conversion price is $1.9953.","Securities issued under Section 4(a)(2)/Rule 506 exemption without registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136656,"accession_number":"0001641172-25-020406","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"INVO Fertility 1-for-3 reverse stock split effective July 21, 2025 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:3 effective pre-market July 21, 2025; new CUSIP 44984F708.","Post-split shares outstanding ~928,272; authorized shares reduced to 1,388,888.","Fractional shares rounded up to whole shares; no fractional shares issued.","Split intended to meet Nasdaq $1.00 minimum bid price requirement; no compliance guarantee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136655,"accession_number":"0001641172-25-018529","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"INVO Fertility adjourns annual meeting to July 23; vote on proposal 3 pending","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Annual meeting initially held June 25; votes on proposals 1,2,4,5,6,7,8 completed.","Meeting reconvened July 9 and adjourned to July 23 at 12:00 pm ET for proposal 3.","Adjourned meeting will be virtual at www.virtualshareholdermeeting.com/INVO2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136654,"accession_number":"0001641172-25-017280","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"INVO Fertility amends SPA, exchanges $1.8M debenture for preferred shares, issues inducement shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to SPA allows Holder to exchange up to $10M of C-2 Preferred for Debenture, minimum $200k.","Holder exchanges $1.8M principal plus accrued interest of Debenture for 1,800 shares of C-2 Preferred.","As inducement, Company issues 630 new unregistered C-2 Preferred shares to Holder (35% of exchanged amount).","Company agrees to 30-trading-day standstill on share issuances and one-year ban on Variable Rate Transactions.","On June 26, 2025, Holder exercised $500k AIR for cash; conversion price adjusted to $0.95 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153862,"accession_number":"0001641172-25-016484","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"INVO Fertility holds annual meeting; proposal to increase authorized shares to 50M adjourned to July 9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Davis, Messina, Ryan, Shum, Szot.","Ratification of M&K CPAs PLLC as auditor approved with 779,963 votes for.","Shareholders approved issuance on conversion of Series C-2 Preferred, $4.8M debenture, and Inducement Warrants.","Stock incentive plan amended to 1.2M shares (approx 10% fully diluted).","Proposal 3 (increase authorized shares from 4.17M to 50M) adjourned to July 9 for further solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153861,"accession_number":"0001641172-25-014019","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"INVO Fertility divests majority holdings in NTI, retains preferred stake and note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Effective June 2, 2025, INVO redeemed all Series C-1 Preferred for 3,227,813 shares of NTI Class A Common, ceasing to hold NTI common.","INVO retains 6,300 shares of NTI Series A Preferred, representing 19.9% on an as-converted basis, and a $4.8M secured convertible note from NTI.","Pro forma net loss improves: Q1 2025 from $17.4M to $16.2M; FY 2024 from $9.1M to $5.7M after removing NTI operations.","The divestiture removes NTI's intangible assets ($14.8M) and goodwill ($3.0M) from INVO's balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153860,"accession_number":"0001641172-25-013122","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","3.02","3.03","5.02","5.03","8.01"],"status":"ready","headline":"INVO restructures NTI holdings with $4.8M note and preferred stock amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 801,196 NTI shares (19.9% stake) for 6,300 NTI Series A Preferred shares, $1,000 stated value each.","NTI issued INVO a $4.8M secured convertible promissory note at 7%, due Nov 2026, convertible upon Qualified IPO or sale.","Exchanged Series C-1 Preferred held by GreenBlock and FNL for Series C-2 Preferred; amended certificates to add redemption rights and reduce conversion price to $1.61.","Amended and Restated Debenture with FNL: $4.8M principal, maturity extended to Feb 2026, plus right to buy up to $10M additional Series C-2 Preferred.","Decathlon and FNL released security interests in NTI assets to facilitate the transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153859,"accession_number":"0001641172-25-011842","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.","Net loss of $17.4M vs $1.6M; includes $14.6M non-cash impairment on NAYA Therapeutics assets.","Adjusted EBITDA loss widened to $(606,551) from $(427,467) in prior year.","Company refocuses on fertility after April 2025 decision to divest majority stake in NAYA TX.","CEO cites supportive policy shifts and aims for cash flow break-even through clinic expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1637185.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153855,"accession_number":"0001641172-25-008353","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K/A","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"INVO Fertility induces warrant exercise at $1.61/share, issues new warrants for 698,760 shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Institutional holder exercises existing warrants for 465,840 shares at reduced price of $1.61, gross proceeds ~$750,000.","Company issues new warrants to purchase 698,760 shares (150% of exercised) at $1.61, exercisable after stockholder approval, 5-year term.","Company must seek stockholder approval at 2025 annual meeting; if not obtained, meetings every 90 days until approval.","Company agrees to 30-trading day lockup on equity issuance and no variable rate transactions for 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153858,"accession_number":"0001641172-25-007603","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"INVO Fertility induces exercise of $8.40 warrants at $1.61, receives ~$750k gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercised 465,840 existing warrants at reduced exercise price of $1.61 per share.","Company issued new unregistered warrants for 698,760 shares at $1.61, exercisable post-Nasdaq stockholder approval.","Gross proceeds ~$750k; original warrants had $8.40 exercise price.","Company must hold stockholder meeting within 90 days to approve new warrant issuance.","30-day trading restriction on further issuances and one-year ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153857,"accession_number":"0001641172-25-006798","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).","Net loss widened to $(9.1)M in FY2024 from $(8.0)M, driven by NAYA Therapeutics merger costs.","Adjusted EBITDA improved to $(2.2)M in FY2024 from $(4.9)M in FY2023.","Company announced intent to divest majority stake in NAYA TX to refocus on fertility clinic operations.","Management cites declining U.S. fertility rate and rising ART demand as expansion catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1637185.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153856,"accession_number":"0001641172-25-005359","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01","5.03","9.01"],"status":"ready","headline":"INVO Fertility (fka NAYA) receives Nasdaq delisting notice for late 10-K; changes name to INVO Fertility","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on April 16, 2025 for failure to file 2024 10-K on time; 60 days to submit compliance plan.","If plan accepted, Nasdaq may grant exception until October 13, 2025 to regain compliance.","Company expects to file the 10-K as soon as practicable.","Effective April 14, 2025 changed name from NAYA Biosciences to INVO Fertility, Inc.; intends to trade under ticker 'IVF' on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153863,"accession_number":"0001641172-25-003972","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NAYA shareholders elect all five director nominees and ratify auditor M&K CPAs at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Trent Davis, Rebecca Messina, Barbara Ryan, Steven Shum, and Matthew Szot each elected with over 2.2 million votes for.","Broker non-votes were 1,973,786 for each director; total votes cast represented a quorum of 4,358,438 shares.","Ratification of M&K CPAs PLLC as independent auditor for FY 2024 passed with 4,311,854 votes for, 34,533 against, 12,051 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172533,"accession_number":"0001641172-25-001807","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"NAYA regains Nasdaq compliance after reverse split; delisting averted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received delisting determination on Mar 25, 2025 for failing to meet $1.00 bid price rule.","Executed 1-for-12 reverse stock split on Mar 18, 2025 to address bid price deficiency.","By Mar 31, 2025, closing bid price exceeded $1.00 for 10 consecutive days.","Nasdaq staff confirmed compliance on Mar 31, 2025, closing the delisting matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172532,"accession_number":"0001641172-25-000316","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"NAYA Biosciences executes 1-for-12 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 12:01 a.m. ET on March 18, 2025; stock trades under same symbol 'NAYA'.","Post-split shares outstanding approx. 666,057; authorized shares reduced to 4,166,666.","Fractional shares rounded up to next whole share; new CUSIP number 44984F609.","Split intended to meet Nasdaq $1.00 minimum bid price requirement for continued listing.","No assurance that reverse split will enable compliance with Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172531,"accession_number":"0001493152-25-009549","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Naya Biosciences postpones 2024 annual meeting to April 9, 2025; all prior votes void","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting postponed from March 10 to April 9, 2025; new record date set for March 10, 2025.","Standard proposals (director election, auditor ratification) have sufficient votes; special proposals (share issuance, plan amendment, authorized shares) lack required votes.","All votes cast under the February proxy are null and void; new proxy card will be issued.","Nasdaq granted extension until June 30, 2025 to regain compliance with annual meeting rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172530,"accession_number":"0001493152-25-002543","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["1.01","2.04","3.01","7.01","9.01"],"status":"ready","headline":"NAYA Biosciences Prices $9.5M Public Offering and Receives Nasdaq Notice for Missing Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NAYA Biosciences closed public offering of 13,615,171 units at $0.70 per unit, raising approximately $9.5 million in gross proceeds.","Company intends to use $2.5M for Wisconsin Fertility Institute, $4M to redeem 4,000 Series C-2 preferred shares, and up to $1.95M for debt repayment.","Nasdaq notified NAYA on Jan 10, 2025 for failing to hold annual meeting within 12 months of fiscal year end; company plans ASM in March 2025.","Offering triggered redemption of $500,000 principal on 7% Senior Secured Convertible Debenture held by FNL and repayment of notes to FirstFire and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172529,"accession_number":"0001493152-25-001258","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NAYA Biosciences posts updated corporate presentation on website; no details available from filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an 8-K on January 7, 2025, indicating an updated corporate investor presentation was posted.","Presentation attached as Exhibit 99.1 but no specific content provided in the filing extract.","Unable to extract any new financial figures, strategic updates, or material changes from available text.","Investor should refer to the full presentation on the company's website for actual content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189524,"accession_number":"0001493152-24-049815","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K/A","filed_at":"2024-12-12T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"NAYA Biosciences completes merger with Legacy NAYA; stock and debt exchange detailed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Legacy NAYA share exchanged for 118,148 NAYA common shares and 30,375 Series C-1 Preferred shares (convertible only after stockholder approval).","$8.58M Legacy NAYA debt converted into 669,508 common shares and 8,576 Series C-2 Preferred; remaining $3.93M exchanged for new 7% Senior Secured Convertible Debenture due Dec 2025.","Dr. Daniel Teper appointed President; CEO Steven Shum and CFO Andrea Goren remain; Teper and Lyn Falconio join board of directors.","Legacy NAYA audited results: no revenue for 2022 or 2023; net loss $3.28M in 2023, $9.5M in 2022; going concern noted.","Stockholder meeting required to ratify merger, increase authorized shares to 100M, and approve reverse stock split (1:2 to 1:20)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189525,"accession_number":"0001493152-24-044278","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NAYA Biosciences regains Nasdaq equity compliance; faces one-year monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice dated Oct 30, 2024 confirming compliance with Listing Rule 5550(b)(1) (Equity Rule).","Compliance follows June 18, 2024 Panel decision; company under mandatory panel monitor for one year.","No financial results or operational updates disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189523,"accession_number":"0001493152-24-041062","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"INVO Bioscience completes acquisition of NAYA, changes name to NAYA Biosciences","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["NAYA stockholders receive 118,148 INVO common shares and 30,375 Series C-1 Preferred per share.","$8.58M NAYA debt converted into 669,508 INVO common shares and 8,576 Series C-2 Preferred.","Remaining $3.93M NAYA debt exchanged for 7% convertible debenture due December 2025.","Name changed to NAYA Biosciences, Inc.; ticker to change from INVO to NAYA on Nasdaq.","Dr. Daniel Teper appointed President and board director; Lyn Falconio also named to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189522,"accession_number":"0001493152-24-039059","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"INVO Bioscience enters $265k cash advance; senior lender imposes equity raise condition to avoid interest hike","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Cedar Advance LLC purchased $384,250 of future sales for gross $265,000; net proceeds $251,750.","Weekly payments of $9,606 until purchase price repaid; proceeds for working capital.","Decathlon amendment: if INVO fails to raise $1M net equity by Nov 30, 2024, minimum interest multiples rise 0.15x.","Cedar Advance subordinated to Decathlon's senior lien via separate agreement.","Transaction authorized by Decathlon under restated first amendment to revenue loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206026,"accession_number":"0001493152-24-037589","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01","4.02","9.01"],"status":"ready","headline":"INVO Bioscience receives Nasdaq bid-price deficiency notice; restates lease accounting for 2021–2024 periods","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified INVO on Sep 18, 2024, that bid price was below $1 for 34 consecutive days; 180-day cure to May 17, 2025.","If not compliant by May 17, 2025, a second 180-day period may be granted if other initial listing standards are met.","Company considering reverse stock split among options to regain compliance.","Audit committee concluded financial statements from Jun 2021–Jun 2024 should no longer be relied upon due to incorrect discount rate used for operating lease ROU assets/liabilities.","Restatement does not affect revenue, results, EPS, or net equity; no change to operations or compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206025,"accession_number":"0001493152-24-037027","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"INVO Bioscience amends merger with NAYA; extends deadline to Oct 14, revised consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["NAYA purchased 27,500 Series A preferred shares for $137,500 on Sept 16, 2024 per Securities Purchase Agreement.","NAYA may buy up to additional 72,500 Series A shares for $362,500 before or at closing; prior breaches waived.","Revised merger consideration: ≤19.9% of INVO common stock pre-merger plus new Series C convertible preferred.","After stockholder approval, Series C converts to common representing ~60.1% of INVO outstanding shares.","NAYA to transfer 85% of common stock payment shares to secured lender Five Narrow Lane LP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206024,"accession_number":"0001493152-24-032181","cik":1417926,"company_name":"INVO Fertility, Inc.","ticker":"IVF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INVO Bioscience Q2 2024 revenue surged 481% to $1.84M; adjusted EBITDA improved by $1.1M to $(0.5)M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,836,597, up 481% YoY ($315,902); clinic revenue up 611% to $1,807,921.","Net loss remained $(2.2) million; total operating expenses rose to $3.7M, including $1.0M non-cash expense.","Adjusted EBITDA improved to $(0.5) million from $(1.6) million in Q2 2023.","All three fertility centers (Middleton, Atlanta, Birmingham) reported sequential revenue growth and are collectively profitable.","Merger with NAYA Biosciences (all-stock) still in discussions for further extension; $25K in transaction costs incurred in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":3412883.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2633294.104375,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-14T23:59:59+00:00|206024"}